T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity of second-line T-DM1 after front-line pertuzumab-based therapy.
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study / Conte, Benedetta; Fabi, Alessandra; Poggio, Francesca; Blondeaux, Eva; Dellepiane, Chiara; D'Alonzo, Alessia; Buono, Giuseppe; Arpino, Grazia; Magri, Valentina; Naso, Giuseppe; Presti, Daniele; Mura, Silvia; Fontana, Andrea; Cognetti, Francesco; Molinelli, Chiara; Pastorino, Simona; Bighin, Claudia; Miglietta, Loredana; Boccardo, Francesco; Lambertini, Matteo; Del Mastro, Lucia. - In: CLINICAL BREAST CANCER. - ISSN 1526-8209. - 20:2(2020), pp. 181-187. [10.1016/j.clbc.2019.09.001]
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study
Buono, Giuseppe;Arpino, Grazia;Naso, Giuseppe;
2020
Abstract
T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity of second-line T-DM1 after front-line pertuzumab-based therapy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
